news, journals and articles from all over the world.
Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated in a preclinical study a potential new therapeutic approach to treating the most common form of lung cancer. The strategy involves inhibiting the immune-system molecule TREM2 while enhancing natural killer cells (the so-called protectors of the immune system). It was described in the April 20 online issue of Nature Immunology.
Wake Forest University School of Medicine has been awarded a five-year, $2.7 million grant from the National Cancer Institute to investigate lung cancer health disparities. Researchers will focus on developing novel treatments that target genetic, immunologic and metabolic changes that disproportionally affect Black patients with non-small cell lung cancer (NSCLC).
A new study led by researchers at The University of Texas MD Anderson Cancer Center discovered that co-occurring mutations in three tumor suppressor genes – KEAP1, SMARCA4 and CDKN2A – are linked with poor clinical outcomes in patients with KRAS G12C-mutant non-small cell lung cancer (NSCLC) treated with the KRAS G12C inhibitors adagrasib or sotorasib.
A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone for patients with operable non-small cell lung cancer (NSCLC), according to Phase III trial results presented today by researchers from The University of Texas MD Anderson Cancer Center at the American Association for Cancer Research (AACR) Annual Meeting 2023.
Cedars-Sinai Cancer oncologists and researchers are available to comment on late-breaking topics and research throughout the American Association for Cancer Research (AACR) Annual Meeting 2023, happening April 14-19 in Orlando.
Article title: Lung cancer-kidney cross talk induces kidney injury, interstitial fibrosis, and enhances cisplatin-induced nephrotoxicity Authors: Andrew Orwick, Sophia M. Sears, Cierra N. Sharp, Mark A. Doll, Parag P. Shah, Levi J. Beverly, Leah J. Siskind From the authors: “This…
A new study from the Harvey L. Neiman Health Policy Institute found that only 1.8% of eligible Americans with commercial insurance received lung cancer screening. Rates were higher but still extremely low for Original Medicare (3.4%) and Medicare Advantage (4.6%). The study, published in the Journal of the American College of Radiology, determined 2017 screening rates for patients who were eligible for lung cancer screening by low-dose computed tomography (LDCT), as determined United States Preventive Services Task Force guidelines.
A new study finds some patients with early-stage lung cancer who receive a lobectomy do not fare better than patients who have less lung tissue removed.
In a Phase II trial led by researchers from The University of Texas MD Anderson Cancer Center, adding ipilimumab to a neoadjuvant, or pre-surgical, combination of nivolumab plus platinum-based chemotherapy, resulted in a major pathologic response (MPR) in half of all treated patients with early-stage, resectable non-small cell lung cancer (NSCLC).
A new study represents a first step towards generating highly detailed 3-dimensional maps of lung tumors using genetically engineered mouse models.
New data released from the ADAURA Phase III trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a significant improvement in overall survival, compared to placebo in the adjuvant treatment of patients with early stage EGFR-mutated lung cancer. Roy S. Herbst, MD, PhD, deputy…
Lung cancer patients with moderate to severe depression are 2 to 3 times more likely to have inflammation levels that predict poor survival rates, a new study found. The results may help explain why a substantial portion of lung cancer patients fail to respond to new immunotherapy and targeted treatments that have led to significantly longer survival for many people with the disease.
A compound found in cigarette and industrial smoke, benzo(a)pyrene (BaP), is known to damage DNA. Now, researchers reporting in ACS Central Science have mapped these effects for the first time in human lung cells after BaP exposure, which could help predict exposures that lead to cancers.
MD Anderson announced licensing agreements with BostonGene and Tempus for the MD Anderson EGFR Classification, which organizes EGFR mutations into subgroups that may guide clinical decision-making.
A new study by researchers at Washington University School of Medicine in St. Louis found that the quality of care for lung cancer in the U.S. varies widely. The findings show that high-quality care is associated with improved overall survival rates among patients with lung cancer.
Columbia Engineering researchers report that they have developed a new experimental pipeline to combine bacterial therapy with current cancer drugs. Their study, which explores resistance to bacterial therapy at the molecular level, has achieved better treatment efficacy without additional toxicity in laboratory models.
The U.S. Food and Drug Administration has approved the targeted imaging agent Cytalux (pafolacianine) for use in lung cancer surgery. This injectable diagnostic binds to cancerous tissue and glows when stimulated by near-infrared light, making it easier for surgeons to remove tumors completely while sparing healthy tissue. Thoracic surgeons at the Center for Precision Surgery in the Abramson Cancer Center at Penn Medicine led the clinical trials evaluating the imaging agent in lung cancer, in a partnership with On Target Laboratories.
“Our new Ion Bronchoscopy system is a robotic-assisted minimally invasive biopsy platform. It features an ultra-thin, ultra-maneuverable catheter that allows navigation far into the lung, reaching smaller airways, said Faiz Y. Bhora, MD, FACS, chair of surgery, and chief of thoracic surgery, central region, Hackensack Meridian Health. “This platform’s unprecedented stability enables the precision needed for biopsy compared to manual techniques and the ability to diagnose lung cancer at the earliest stage when it is most treatable.”
Sean P. Pitroda, MD, Assistant Professor of Radiation and Cellular Oncology at the University of Chicago, has received a Lung Cancer Discovery Award and been selected to join the American Lung Association Research Team for his work to improve treatment response in patients with metastatic non-small-cell lung cancer (mNSCLC).
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts.
While it may seem common knowledge that smoking is bad for your lungs, if and how ultrafine particles present in cigarette smoke impact the development and progression of lung cancer remains unclear.
A new study by researchers at Washington University School of Medicine in St. Louis found that undergoing more frequent computed tomography (CT) scans was not associated with improved outcomes following lung cancer surgery. Less frequent CT scans may reduce health-care costs, patient anxiety.
Diagnosing early-stage lung cancer with low-dose computed tomography (CT) screening drastically improves the survival rate of cancer patients over a 20-year period, according to a large-scale international study being presented by Mount Sinai researchers at the annual meeting of the Radiological Society of North America.
Stigma can have profound and lasting effects, and studies have shown that people living with lung cancer may encounter challenges in receiving the support they need from their social network and healthcare providers. Memorial Sloan Kettering Cancer Center (MSK) is committed to helping eliminate the stigmas associated with a lung cancer diagnosis and is working to raise awareness in collaboration with other national organizations.
Joint call to action urges individuals, providers and insurers to increase access to and utilization of low-dose CT screening for those at high risk for lung cancer.
Free online event for cancer patients and caregivers featuring immunotherapy experts and patient advocates taking place Nov. 11-12, 2022.
Lung cancer is by far the leading cause of cancer death, making up nearly 25 percent of all cancer deaths. More than 130,000 U.S. adults die from lung cancer each year – more than breast, colon and prostate cancer deaths…
A cohort study of more than one million people has found that most persons screened for lung cancer meet U.S. Preventative Services Task Force (USPSTF) criteria, but men, persons who formerly smoked, and younger eligible patients are less likely to be screened. Adherence to follow-up screening was also poor. The findings are published in Annals of Internal Medicine.
All organs are vital to sustaining life, and all require oxygen to properly function. This is what makes our lungs important and why maintaining healthy lungs is critical. Sometimes that’s as easy as not smoking, avoiding pollutants, and exercising. Other…
New study data shows that the immuno-oncology drug, atezolizumab is a safe and effective treatment for stage IB-IIIB non-small cell lung cancer patients prior to lung cancer surgery, according to a new study led by researchers with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute as part of the national Lung Cancer Mutation Consortium 3 study.
Researchers found that the survival of patients in this new study was far better – about 80% at three years post treatment and approximately twice as good as that which would be expected with surgery and chemotherapy alone. Study investigators also report data showing that the presence of high numbers of natural killer (NK) cells – a type of immune cell found in the blood before treatment – were associated with poor immunotherapy treatment effectiveness in this study. Patients with high levels of these cells might benefit from the addition of NK-specific therapy.
MD Anderson researchers used extensive single-cell analysis to create a spatial map of tumor-infiltrating B cells and plasma cells in early-stage lung cancers, revealing new roles for these immune cells in cancer development and immunotherapy responses.
MD Anderson and Erasca announced a strategic research and development collaboration to evaluate multiple agents from Erasca’s pipeline targeting the RAS/MAPK pathway in cancer.
Mount Sinai is leading a team of lung cancer researchers that has been awarded a three-year, $500,000 grant from Stand Up To Cancer® (SU2C) to explore therapeutic approaches to lung tumors with mutations in the KRAS gene, an undertaking that could have a significant impact for a large population of cancer patients who currently lack effective treatment options.
Sexual dysfunction is highly prevalent in women with lung cancer with most survey participants reporting little to no interest in sexual activity, according to research led by Narjust Florez (Duma), MD, associate director for the Cancer Care Equity Program at Dana-Farber Cancer Institute. The research was presented today at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2022.
A clinical trial is only as powerful as its participants. For years, researchers have struggled to fill clinical trials and enroll sufficiently diverse groups of patients for results to reflect the broader population, in part because of stringent guidelines on who can participate.
In Indian Ayurvedic medicine, black cardamom has been used in formulations to treat cancer and lung conditions. A team of NUS researchers studied the scientific basis behind this traditional medicinal practice and provided evidence of the cytotoxic effect of black cardamom on lung cancer cells. The findings could potentially lead to the discovery of safe and effective new bioactives which can prevent or cure cancer formation.
While we’re still dealing with the pandemic, it’s fairly common to associate any signs of health abnormality with COVID, even months after you’ve had the virus, but there are some warning signs that may be an indication of lung cancer. …
New Cleveland Clinic research has uncovered key information about cellular interaction between tumor cells and normal tissue, providing better understanding of how therapeutic resistance develops. Findings published in Science Advances.
Researchers at Washington University School of Medicine in St. Louis are leading a national study aimed at identifying patients with early-stage lung cancer who are at high risk of having the cancer return, even after surgery and chemotherapy appear to have eliminated their tumors. The research is supported by a $5.3 million grant from the National Cancer Institute of the National Institutes of Health (NIH).
Building on Penn Medicine’s years of research and use of imaging technology that illuminates tumor tissue—helping clinicians more easily detect and remove it—the Perelman School of Medicine at the University of Pennsylvania has received a five-year, $9 million research grant from the National Cancer Institute (NCI) to push the field forward, particularly for lung cancer patients.
A study led by the University of California, Irvine shows a strong relationship between prolonged exposure to low levels of radon and lung cancer, indicating a need for enhanced protection measures. Radon gas in the air decays into tiny radioactive particles which can damage lung cells and lead to cancer.
An inhaled immunotherapy successfully treated cancer in some companion dogs as part of a clinical trial conducted by UC Davis oncology and veterinary researchers. Recently published study results show potential for fighting cancer in humans as well.
Nearly 43% of patients with non-small cell lung cancer (NSCLC) whose lung cancers harbored a specific KRAS mutation responded to the experimental drug adagrasib, and the targeted agent also showed activity against lesions in the brain that metastasized from the lung tumors, according to results of a study led by Dana-Farber Cancer Institute investigators.
Henry Ford Health is the first in the world to complete a full course of patient treatments using the latest advancement in magnetic resonance (MR)-guided radiation therapy, which integrates real-time magnetic resonance imaging (MRI) and linear acceleration to deliver precise and accurate radiation treatment more rapidly than ever before.
Mount Sinai researchers have validated for the first time that a simple blood test called a liquid biopsy could be a better predictor of whether cancer immunotherapy will be successful for a patient with lung cancer than an invasive tumor biopsy procedure. Their study was published in the Journal of Experimental & Clinical Cancer Research in June.
Case Western Reserve University has signed an exclusive license agreement with Picture Health that aims to turn the promise of AI tools into a reality that ultimately benefits patients around the globe.
Researchers at the Abramson Cancer Center at the University of Pennsylvania have found a way to identify lung cancer at the cellular level in real time during a biopsy, offering promise in the ability to detect the disease earlier and with more confidence. The research is published this week in Nature Communications.
The first study to look at follow-up for patients deemed at high risk for lung cancer after CT screening found that 47 percent delayed follow-up care, according to research published at the ATS 2022 international conference.
UC Davis Health physicians have performed the first single anesthesia diagnosis to treatment of lung cancer utilizing a fully robotic approach in the UC Health System. Procedure allows physicians to diagnose and remove lung cancer mass during single surgery.
Featured studies include clinical advances with a new combination therapy targeting angiogenesis in platinum-resistant ovarian cancer and a promising immunotherapy combination for kidney cancer, plus laboratory studies that focus on targeting ferroptosis in specific lung cancers, developing chimeric antigen receptor (CAR) T cell therapies for blastic plasmacytoid dendritic cell neoplasms, and characterizing racial and ethnic disparities in breast cancer early detection.
English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
Urdu